Toggle Main Menu Toggle Search

Open Access padlockePrints

The Newcastle University research output collection, currently available on ePrints, will shortly be moving to a new open repository platform, Figshare. To prepare for the data migration we have paused adding new content to ePrints, and will resume once the new repository is launched. During this time you will continue to have access to ePrints (but no new content will appear). We will share updates here when available.

Evaluation of real-world use of pulmonary embolism thrombolysis: Erupt

Lookup NU author(s): Dr Joe Kibbler, Professor Anthony De SoyzaORCiD

Downloads


Licence

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).


Abstract

© The authors 2025.Introduction International guidelines recommend systemic thrombolysis for high-risk acute pulmonary embolism (PE). Significant uncertainties remain regarding thrombolysis in non-high-risk PE and the use of reduced-dose thrombolysis. To address this, UK respiratory trainees led a multicentre UK-wide study assessing current practice. Our primary aim was to evaluate UK practice against the European Society of Cardiology recommendations (specifically to utilise full-dose thrombolysis only in high-risk PE). Secondary outcomes included mortality and an analysis of clinical factors associated with administrating reduced-dose thrombolysis. Method This was a retrospective multicentre observational study evaluating thrombolysis of acute PE from September 2021 to September 2022 in 26 centres across the UK. Results A total of 174 patients from 26 sites were included, with fibrinolytic dose recorded in 168 (96.6%) cases. After exclusion of 30 cases involving cardiac arrest, 26 out of 138 patients (18.8%) received reduced-dose thrombolysis. 67 (39.9%) patients underwent thrombolysis for non-high-risk PE. Factors associated with receiving reduced-dose thrombolysis included higher age (p=0.005), higher Charlson comorbidity index (p=0.008) and higher serum lactate (p=0.02). Conclusion PE thrombolysis in the UK deviates from international guidelines in a significant minority of cases; comprising the use of reduced-dose regimens and thrombolysis in non-high-risk cases without haemodynamic deterioration. Prospective real-world studies, assessing clinical practice and outcomes following thrombolysis, should be conducted to understand the pragmatic application of evidence and inform future guidelines.


Publication metadata

Author(s): Sobala R, Kibbler J, Yip K, Thompson R, Rafique C, Steward M, Samanta R, Jha A, Rahman N, De Soyza A

Publication type: Article

Publication status: Published

Journal: ERJ Open Research

Year: 2025

Volume: 11

Issue: 3

Print publication date: 01/05/2025

Acceptance date: 13/12/2024

Date deposited: 04/08/2025

ISSN (electronic): 2312-0541

Publisher: European Respiratory Society

URL: https://doi.org/10.1183/23120541.00935-2024

DOI: 10.1183/23120541.00935-2024

Data Access Statement: All data are included in the article.


Altmetrics

Altmetrics provided by Altmetric


Share